Vol. 20/No. 18 | OncologyLive

Workplace Accommodations Would Ease the Burden for Patients With Cancer

September 26, 2019

Women with breast cancer who have lower incomes and are members of minority populations are less likely to return to work following surgery and chemotherapy, and oncologists need to help them obtain workplace accommodations to ease their return to employment.

The Prostate Cancer Paradox Revisited

September 25, 2019

Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.

Therapeutic Vaccines Lead the Charge in HPV-Driven Cancers

September 24, 2019

The development of therapeutic vaccines for patients with cancers associated with the human papillomavirus has emerged as a leading strategy in continuing research efforts to address the growing public health threat posed by the virus.

Small Subgroups May Hold Big Clinical Clues in Oncology

September 23, 2019

With the revolution in our understanding of cancer’s basic molecular biology, it is increasingly evident that subgroups of cancer originating from specific regions of the body have unique natural histories and respond to very different therapeutics. For example, the importance of BRCA mutations, which define a subset of ovarian cancers impressively sensitive to PARP inhibitors, has striking altered the management of this group of gynecologic malignancies.

The FDA Could Help Address Financial Toxicity During the Approval Process

September 21, 2019

Given the widespread financial impact the high cost of cancer drugs has on the healthcare system, it may be time for the FDA to take a broader approach when reviewing oncology drug applications. By also examining the cost of the drug, the FDA could shine a light on escalating drug costs and play a leadership role in creating new programs and initiatives that help patients pay for promising new therapies.

Experts Dissect Key Findings for Progressive Gastric and GEJ Cancers

September 20, 2019

Although chemotherapy combinations remain standard first-line therapy for advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, strategies for progressive disease have shifted to include antiangiogenic agents and immunotherapy.